Science and Enterprise

Tag: biotechnology

  • FDA Approves Subcutaneous Delivery of Immunodeficiency Drug

    Talecris Biotherapeutics, a biotechnology company in Research Triangle Park, North Carolina said today that the U.S. Food and Drug Administration (FDA) approved its Gamunex-C drug for subcutaneous administration in the treatment of primary immunodeficiency (PI). Subcutaneous administration — illustrated right — delivers the product under the skin into the subcutaneous tissue and intravenous administration is…

  • Patent Issued to Biotech for DNA Libraries

    Dyadic International Inc.,  a biotechnology company in Jupiter, Florida says it has been issued Patent No. 7,794,962 by the United States Patent and Trademark Office on its method for the expression and subsequent screening of DNA libraries in filamentous fungal hosts. The company says the patented technology can help speed up the discovery of genes…

  • Biotech Develops Faster Bacteria Diagnostics

    NanoLogix Inc., a biotechnology company in Hubbard, Ohio has unveiled a new line of tests to detect and identify aerobic live-cell bacteria. NanoLogix’s Quick-Tests, says the company, offers the research community high-sensitivity analysis results in reduced time with lower costs than traditional technologies. NanoLogix says its Quick-Tests detect and identify live-cell bacteria, such as E.coli,…

  • Biopharm Company Consolidates, Cuts 25% of Workforce

    Halozyme Therapeutics Inc., a biopharmaceutical company in San Diego, California said on Monday it would reduce its new research and development work to concentrate on existing drug products and commitments to pharmaceutical manufacturers. This consolidation will result in the company cutting its workforce by 25 percent. The company’s announcement noted Halozyme Therapeutics will focus its…

  • ImmunoGen, Novartis to Collaborate on Cancer Drugs

    ImmunoGen Inc., a biotechnology company in Waltham, Massachusetts, said today it has a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis, a pharmaceutical manufacturer headquartered in Basel, Switzerland. Under the agreement, Novartis will pay a $45 million fee to ImmunoGen for…

  • Biotech, Pharma Companies Partner on Schizophrenia Research

    Takeda Pharmaceutical Company, a global drug manufacturer in Osaka, Japan, and Envoy Therapeutics Inc., a drug discovery company in Jupiter, Florida, said today they formed a three-year research alliance aimed at discovering drugs for schizophrenia with greater efficacy and safety compared to current therapies. Envoy’s technology, called bacTRAP, combines genetic engineering with molecular biology techniques…

  • Three Companies Win NIH Biodefense Research Contracts

    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded three new contracts to fund research on vaccines and vaccine delivery against dengue fever and anthrax that could be used in a terror attack. Total funding for the three contracts could reach $68 million, depending on the successful…

  • GlaxoSmithKline to Back Biotech Company

    Global drug maker GlaxoSmithKline (GSK), headquartered in London, says it will take an 18 percent equity stake in Convergence Pharmaceuticals Ltd., a new biotech company developing analgesic compounds, often used in over-the-counter pain relievers. Convergence Pharmaceuticals was officially launched on 4 October. The company has raised $35.4 million in Series A (early-stage) financing from a…

  • FDA Okays Myelodysplastic Syndromes Trial Protocol

    Onconova Therapeutics Inc., a biotech company in Newtown, Pennsylvania, says it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of a Phase 3 clinical trial for the company’s drug Estybon. The drug is a monotherapy for patients with myelodysplastic syndromes (MDS), diseases affecting…

  • Stanford Univ. Licenses IVF Technology

    Auxogyn Inc., a medical technology company in Menlo Park, California  says it acquired an exclusive license from Stanford University to develop products that can help improve the effectiveness of in vitro fertilization (IVF) procedures. Auxogyn specializes in technologies for women’s reproductive health. A new paper describing the technology licensed from Stanford demonstrates that a human…